Sudi Bio was established in the Cayman Islands in February 2019 and has operating subsidiaries in the United States and China. The company is a clinical-stage global biopharmaceutical company that develops and delivers novel oral therapies to treat a variety of chronic diseases to meet medical needs. The Company's differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling the Company to develop oral small molecule therapies for the treatment of various diseases, including those affecting the metabolic, cardiovascular and pulmonary systems. 

Expected P&L on Expiry

Key Stats

Pricing Model

About GPCR20260220C80